IFW

Docket No.: TNA-005.05
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Jin-An Jiao *et al.*

Application No.: 10/764,140 Confirmation No.: 6085

Filed: January 22, 2004 Art Unit: 1646

For: ANTIBODIES FOR INHIBITING BLOOD COAGULATION AND METHODS OF USE THEREOF Examiner: C. M. Borgeest

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

UNDER CFR 1.97(c)(2)

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97(c)(2), and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

As part of this Information Disclosure Statement, Applicants submit the references that were listed on the Forms 1449 filed on September 30, 2005 and January 19, 2006, but were not considered by the Examiner. In addition, Applicants submit a statement explaining the relevance of Japanese Patent No. 1-503438, which was also submitted in the Information Disclosure Statement filed on January 19, 2006. Applicants respectfully request consideration of these references.

In accordance with 37 CFR 1.98(a)(2)(ii), Applicants have not submitted copies of U.S. patents and U.S. patent applications. Applicants submit herewith copies of foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2).

Applicants have listed dates of publication on the attached PTO-1449 for the cited documents based on information presently available to the undersigned. However, the listed publication dates should not be construed that the information in the cited documents was actually published or otherwise publicly available on the date indicated.

This submission does not represent that a search has been made or that no better art exists. Nor does it constitute an admission that each or all of the listed documents are material or constitute "prior art." Further, if the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents. Moreover, the Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Please charge our Deposit Account No. 06-1448 in the amount of $180.00 covering the fee set forth in 37 CFR 1.17(p). The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our **Deposit Account No. 06-1448, under Reference No. TNA-005.05**. A duplicate copy of this paper is enclosed.

Dated: November 3, 2006

Respectfully submitted,

By _____

Charlene A. Stern-Dombal
Registration No.: 57,961
FOLEY HOAG LLP
155 Seaport Blvd
Boston, Massachusetts 02210
(617) 832-1738
Agent for Applicants

PTO/SB/08a/b (07-06)
Approved for use through 09/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 9

Complete if Known	
Application Number	10/764,140-Conf. #6085
Filing Date	January 22, 2004
First Named Inventor	Jin-An Jiao
Art Unit	1647
Examiner Name	C. M. Borgeest
Attorney Docket Number	TNA-00505

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA*	US-20020025508-A1	02-28-2002	Fechteler et al.	
	AB*	US-20030087372-A1	05-08-2003	DelaCruz et al.	
	AC*	US-20030119075-A1	03-09-2004	Kirchhofer et al.	
	AD*	US-20040229282-A1	11-18-2004	Wong et al.	
	AE*	US-4,644,055	02-17-1987	Kettner et al.	
	AF*	US-4,816,567	03-28-1989	Cabilly et al.	
	AG*	US-5,122,458	06-16-1992	Post et al.	
	AH*	US-5,168,062	12-01-1992	Stinski	
	AI*	US-5,171,662	12-15-1992	Sharma	
	AJ*	US-5,225,539	07-06-1993	Winter et al.	
	AK*	US-5,385,839	01-31-1995	Stinski	
	AL*	US-5,530,101	06-25-1996	Queen et al.	
	AM*	US-5,534,254	07/1996	Huston et al.	
	AN*	US-5,766,886	06-16-1998	Studnicka et al.	
	AO*	US-5,861,267	01-19-1999	Su	
	AP*	US-5,879,677	03-09-1999	del Zoppo	
	AQ*	US-5,889,157	03-30-1999	Pastan et al.	
	AR*	US-5,958,713	09-28-1999	Thastrup et al.	
	AS*	US-5,985,279	11-16-1999	Waldmann et al.	
	AT*	US-5,997,867	12-07-1999	Waldmann et al.	
	AU*	US-6,001,978	12-14-1999	Edgington et al.	
	AV*	US-6,054,297	04-25-2000	Carter et al.	
	AW*	US-6,117,639	09-12-2000	Germann et al.	
	AX*	US-6,245,884	06-12-2001	Hook	
	AY*	US-6,309,636	10-30-2001	do Couto et al.	
	AZ*	US-6,331,415	12-18-2001	Cabilly et al.	
	AA1*	US-6,333,167	12-25-2001	Quinet et al.	
	AB1*	US-6,555,319-A1	04-29-2003	Wong et al.	
	AC1*	US-6,593,291	07-15-2003	Green et al.	
	AD1*	US-6,610,293	08-26-2003	Fischer et al.	
	AE1*	US-6,677,436	01-13-2004	Sato et al.	
	AF1*	US-6,703,494-A1	03-09-2004	Kirchhofer et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
	BA	WO 91/18019	11-28-1991			
	BB	WO 96/13593	05-06-1996			
	BC	WO 96/18105	06-13-1996			
	BD	EP 0 420 937	10/1991			
	BI	JP-1-503438	02/1989			
	BA1	EP 1 069 185	01-17-2001			
	BB1	WO 89/12463	12-28-1989			
	BC1	WO 03/029295	04-10-2003			

Examiner Signature		Date Considered	

PTO/SB/08a/b (07-06)
Approved for use through 09/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/764,140-Conf. #6085
				Filing Date	January 22, 2004
				First Named Inventor	Jin-An Jiao
(Use as many sheets as necessary)				Art Unit	1647
				Examiner Name	C. M. Borgeest
Sheet	2	of	9	Attorney Docket Number	TNA-00505

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	AA1	Alberts et al., "The Cell, 2002, Garland Science, 4th Edition, pp. 161, Fig. 3-42	
	AB1	Benhar et al., "Rapid Humanization of the Fv of Monoclonal Antibody B3 by Using Framework Exchange of the Recombinant Immunotoxin B3(Fv)-PE38," Proc. Natl. Acad. Sci. USA, 91:12051-12055 (1994)	
	AC1	Boulianne et al., "Production of functional chimaeric mouse/human antibody," Nature, 312:643-646 (1984)	
	AD1	Bruggemann et al., "The Immunogenicity of Chimeric Antibodies," J. Exp. Med. 170:2153-2157 (1989)	
	AE1	Cacia et al., "Isomerization of an Aspartic Acid Residue in the Complementarity-Determining Regions of a Recombinant Antibody to Human IgE: Identification and Effect on Binding Affinity," Biochemistry, 35:1897-1903 (1996)	
	AF1	Carter et al., "Humanization of an anti-p185HER2 antibody for human cancer therapy," Proc. Natl. Acad. Sci. USA, 89:4285-4289 (1992)	
	AG1	Casipit et al., "Improving the binding affinity of an antibody using molecular modeling and site directed mutagenesis," Protein Science, 7:1671-1680 (1998)	
	AH1	Co et al., "Humanized antibodies for antiviral therapy," Proc. Natl. Acad. Sci. USA, 88:2869-2873 (1991)	
	AI1	Couto et al., "Anti-BA46 Monoclonal Antibody Mc3: Humanization Using a Novel Positional Consensus and In Vivo and In Vitro Characterization," Cancer Research, 55:1717-1722 (1995)	
	AJ1	Couto et al., "Designing Human Consensus Antibodies with Minimal Positional Templates," Cancer Research (Suppl.) 55:5973s-5977s (1995)	
	AK1	Faber et al., "A Novel Method to Determine the Topology of Peroxisomal Membrane Proteins in Vivo Using the Tobacco Etch Virus Protease," The Journal of Biological Chemistry, 276(39):36501-36507 (2001)	
	AL1	Foote et al., "Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops," J. Mol. Biol., 224:487-499 (1992)	
	AM1	Gorman et al., "Reshaping a therapeutic CD4 Antibody," Proc. Natl. Acad. Sci. USA, 88:4181-4185 (1991)	
	AN1	Griffiths et al., "Human anti-self antibodies with high specificity from phage display libraries," The EMBO Journal, 12(2):725-734 (1993)	
	AO1	Hanes et al., "Picomolar affinity antibodies from a fully synthetic naïve library selected and evolved by ribosome display," Nature Biotechnology, 18:1287-1292 (2000)	
	AP1	Jager et al., "Current Status of Cancer Immunodetection with Radiolabeled Human Monoclonal Antibodies," Seminars in Nuclear Medicine, Vol. XXIII, No. 2, 165-179 (1993)	
	AQ1	Janeway et al., Immunobiology, third edition, Garland Press, pp. 3:7-3:11 (1997)	
	AR1	Kao et al., "Chimeric Antibodies with Anti-Dextran-Derived Complementarity-Determining Regions and Anti-p-Azophenylarsonate-Derived Framework Regions," The Journal of Immumology, 151:1968-1979 (1993)	

Examiner Signature		Date Considered	

PTO/SB/08a/b (07-06)
Approved for use through 09/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/764,140-Conf. #6085
				Filing Date	January 22, 2004
				First Named Inventor	Jin-An Jiao
				Art Unit	1647
(Use as many sheets as necessary)				Examiner Name	C. M. Borgeest
Sheet	3	of	9	Attorney Docket Number	TNA-00505

	AS1	Knappik et al., "Fully Synthetic Human Combinatorial Antibody Libraries (HuCAL) based on Modular Consensus Frameworks and CDRs Randomized with Trinucleotides," J. Mol. Biol., 296:57-86 (2000)	
	AT1	Leong et al., "Adapting pharmacokinetic properties of a humanized anti-interleukin-8 antibody for therapeutic applications using site-specific pegylation," Cytokine, 16(3):106-119 (2001)	
	AU1	LoBuglio et al., "Mouse/human chimeric monoclonal antibody in man: Kinetics and immune response," Proc. Natl. Acad. Sci. USA, 86:4220-4224 (1989)	
	AV1	Mateo et al., "Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity," Immunotechnology, 3:71-81 (1997)	
	AW1	Morrison et al., "Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains," Proc. Natl. Acad. Sci. USA, 81:6851-6855 (1984)	
	AX1	Morrison et al., "Genetically Engineered Antibody Molecules," Advances in Immunology, 44:65-93	
	AY1	Owens et al., "The Generic Engineering of Monoclonal Antibodies," Journal of Immunological Methods, 168:149-165 (1994)	
	AZ1	Padlan, "A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties," Mol. Immun., 28(4/5):489-498 (1991)	
	AA2	Padlan, "Anatomy of the antibody molecule," Molecular Immunology, 31(3):169-217 (1994)	
	AB2	Padlan, "On the Nature of Antibody Combining Sites: Unusual Structural Features That May Confer on These Sites an Enhanced Capacity for Binding Ligands," Proteins, 7:112-124 (1990)	
	AC2	Queen et al., "A humanized antibody that binds to the interleukin 2 receptor," Proc. Natl. Acad. Sci. USA, 86:10029-10033 (1989)	
	AD2	Queen et al., "Cell-Type Specific Regulation of a k Immunoglobin Gene by Promoter and Enhancer Elements," Immunological Reviews, 89:49-68 (1986)	
	AE2	Reichart, "Monoclonal antibodies in the clinic," Nature Biotechnology, 19:819-822 (2001)	
	AF2	Reichmann et al., "Reshaping human antibodies for therapy," Nature, 332:323-327 (1988)	
	AG2	Robertson, "Genentech awarded critical antibody patent," Nature Biotechnology, 20:108 (2002)	
	AH2	Roguska et al., "A comparison of two murine monoclonal antibodies humanized by CDR-grafting and variable domain resurfacing," Protein Engineering, 9(10):895-904 (1996)	
	AI2	Roguska et al., "Humanization of murine monoclonal antibodies through variable domain resurfacing," Proc. Natl. Acad. Sci. USA, 91:969-973 (1994)	
	AJ2	Rudikoff et al., "Single amino acid substitution altering antigen-binding specificity," Proc. Natal. Acad. Sci. USA, 79:1979-1983 (1982)	
	AK2	Saldanha et al., "A single backmutation in the human kIV framework of a previously unsuccessfully humanized antibody restores the binding activity and increases the secretion in cos cells," Molecular Immunology, 36:709-719 (1999)	
	AL2	Shearman et al., "Construction, expression and characterization of humanized antibodies directed against the human α/β T cell receptor," The Journal of Immunology, 147:4366-4373 (1991)	
	AM2	Tan et al., "Superhumanized Antibodies: Reduction of Immunogenic Potential by Complementarity-Determining Region Grafting with Human Germline Sequences: Application to an Anti-CD28," The Journal of Immunology, 169:1119-1125 (2002)	
	AN2	Tempest et al., "Reshaping a human monoclonal antibody to inhibit human respiratory syncytial virus infection in vivo," Bio/Technology, 9:266-271 (1991)	
	AO2	Teng et al., "Construction and testing of mouse-human hetermyelomas for human monoclonal antibody production," Proc. Natl., Acad. Sci. USA, 80:7308-7312 (1983)	
	AP2	Tomizuka et al., "Double trans-chromosomic mice: Maintenance of two individual human chromosome fragments containing Ig heavy and k lock and expression of fully human antibodies," PNAS, 97(2):722-727 (2000)	

Examiner Signature		Date Considered	

PTO/SB/08a/b (07-06)
Approved for use through 09/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/764,140-Conf. #6085
				Filing Date	January 22, 2004
				First Named Inventor	Jin-An Jiao
(Use as many sheets as necessary)				Art Unit	1647
				Examiner Name	C. M. Borgeest
Sheet	4	of	9	Attorney Docket Number	TNA-00505

	AQ2	Vaughan et al., "Human Antibodies with Sub-nanomolar Affinities Isolated from a Large Non-immunized Phage Display Library," Nature Biotechnology, 14:309-314 (1996)	
	AR2	Verhoeyen et al., "Reshaping Human Antibodies: Grafting an Antilysozyme Activity," Science, 239:1534-1536 (1988)	
	AS2	Watson et al., Molecular Biology of the Gene, fourth edition, The Benjamin/Cummings Publishing Company, Inc., p. 840 (1987)	
	DF	Albrecht et al., "An ELISA for tissue factor using monoclonal antibodies," Blood Coagulation and Fibrinolysis, 3:263-270 (1992)	
	DG	Almus et al., "Properties of Factor VIIa/Tissue Factor Complexes in an Umbilical Vein Model," Blood, 76(2):354-360 (1990)	
	DH	Ardaillou et al., "Glomerular tissue factor stimulates thromboxane synthesis in human platelets via thrombin generation," Kidney International, 41:361-368 (1992)	
	DI	Barstad et al., "Procoagulant Human Monocytes Mediate Tissue Factor/Factor VIIa-Dependent Platelet-Thrombus Formation When Exposed to Flowing Nonanticoagulated Human Blood," Arterioslerosis, Thrombosis, and Vascular Biology, 15(1):11-16 (1995)	
	DJ	Beers et al., The Merck Manual of Diagnosis and Therapy, 17th edition, 1999, Merck Research Laboratories, pps. 1654-1681	
	DK	Benedict et al., "Monoclonal Antibody to Tissue Factor Inhibits Intravascular Thrombosis without Imparing Extravascular Hemostasis," JACC, February 1995 Abstract 1012-104, p. 366A	
	DL	Bjoern et al., "Human Plasma and Recombinant Factor VII," The Journal of Biological Chemistry, 266(17):11051-11057 (1991)	
	DM	Broze, George J., Jr., "Binding of Human Factor VII and VIIa to Monocytes," J. Clin. Invest. The American Society for Clinical Investigation, Inc.. 70:526-535 (1982)	
	DN	Carson et al., "An Inhibitory Monoclonal Antibody Against Human Tissue Factor," Blood, 70(2):490-493 (1987)	
	DO	Carson et al., "Monoclonal Antibodies Against Bovine Tissue Factor, Which Block Interaction With Factor VII," Blood, 66(1):152-156 (1985)	
	DP	Cate et al., "The Activation of Factor X and Prothrombin by Recombinant Factor VIIa in Vivo Is Mediated by Tissue Factor," The Journal of Clinical Investigation, Inc., 92:1207-1212 (1993)	
	DQ	Chapman et al., "Regulation of the Procoagulant Activity within the Bronchoalveolar Compartment of Normal Human Lung," Am. Rev. Respir. Dis., 137(6):1417-1425 (1988)	
	DR	Chattopadhyay et al., "Molecular Recognition Sites on Factor Xa Which Participate in the Prothrombinase Complex," The Journal of Biological Chemistry, 267(17):12323-12329 (1992)	
	DS	Clarke et al., "The first epidermal growth factor domain of human coagulation factor VII is essential for binding with tissue factor," Federation of European Biochemical Societies, 298(2,3):206-310 (1992)	
	DT	Collen et al., "New thrombolytic agents and strategies," Bailliere's Clinical Haematology, 8(2):425-435 (1995)	
	DU	Colman, P.M., "Effects of amino acid sequence changes on antibody-antigen interactions," Research in Immunology, 145:33-36 (1994)	
	DV	Contrino et al., "In Situ Characterization of Antigenic and Functional Tissue Factor Expression in Human Tumors Utilizing Monoclonal Antibodies and Recombinant Factor VIIa as Probes," Americal Journal of Pathology, 145(6):1315-1322 (1994)	
	DW	Drake et al., "Functional Tissue Factor Is Entirely Cell Surface Expressed on Lipopolysaccharide-stimulated Human Blood Monocytes and a Constitutively Tissue Factor-producing Neoplastic Cell Line," The Journal of Cell Biology, 109:389-395 (1989)	
	DX	Drake et al., "Selective Cellular Expression of Tissue Factor in Human Tissues," American Journal of Pathology, 134(5):1087-1097 (1989)	
	DY	Fair et al., Cooperative Interaction Between Factor VII and Cell Surface-Expressed Tissue Factor, The Journal of Biological Chemistry, Vol. 262, August 25, 1987, pp. 11692-11698	

Examiner Signature		Date Considered	

PTO/SB/08a/b (07-06)
Approved for use through 09/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 5 of 9

Complete if Known	
Application Number	10/764,140-Conf. #6085
Filing Date	January 22, 2004
First Named Inventor	Jin-An Jiao
Art Unit	1647
Examiner Name	C. M. Borgeest
Attorney Docket Number	TNA-00505

	DZ	Faulk et al., "Tissue Factor: Identification and Characterization of Cell Types in Human Placentae," Blood, 76(1):86-96 (1990)	
	EA	Fay et al., "Mutating factor VIII: lessons from structure to function," Blood Reviews, 19:15-17 (2005)	
	EB	Flössel et al., "Immunohistochemical detection of tissue factor (TF) on paraffin sections of routinely fixed human tissue," Histochemistry, 101:449-453 (1994)	
	EC	Gouault-Heilmann et al., "The Procoagulant Factor of Leukaemic Promyelocytes: Demonstration of Immunologic Cross Reactivity with Human Brain Tissue Factor," British Journal of Haematology, 30:151-158 (1975)	
	ED	Grabowski et al., "The Functional Expression of Tissue Factor by Fibroblasts and Endothelial Cells Under Flow Conditions," Blood, 81(2):3265-3270 (1993)	
	EE	Hamaguchi et al., "FDP D-Dimer Induces the Secretion of Interleukin-1, Urokinase-Type Plasminogen Activator, and Plasminogen Activator Inhibitor-2 in a Human Promonocytic Leukemia Cell Line," Blood, 77(1):94-100 (1991)	
	EF	Hoffman et al., "Human Monocytes Support Factor X Activation by Factor VIIa, Independent of Tissue Factor: Implications for the Therapeutic Mechanism of High-Dose Factor VIIa in Hemophilia," Blood, 83(1):38-42 (1994)	
	EG	Huang et al., "The Mechanism of an Inhibitory Antibody on TF-initiated Blood Coagulation Revealed by the Crystal Structures of Human Tissue Factor, Fab 5G9 and TF 5G9 Complex," J. Mol. Biol., 275:873-894 (1998)	
	EH	Imamura et al., "Role of Macrophage Tissue Factor in the Development of the Delayed Hypersensitivity Reaction in Monkey Skin," Cellular Immunology, 152:614-622 (1993)	
	EI	Ito et al., "Characterization of Functionally Important Regions of Tissue Factor by Using Monoclonal Antibodies," J. Biochem., 114(5):691-696 (1993)	
	EJ	James et al., "Inhibition of tissue factor activity reduces the density of cellular network formation in an in vitro model of angiogensis," Biochemical Society Transactions, 30(2):217-221 (2002)	
	EK	Jang et al., "Antithrombotic Effect of a Monoclonal Antibody Against Tissue Factor in a Rabbit Model of Platelet-Mediated Arterial Thrombosis," Arteriosclerosis and Thrombosis, 12(8):948-954 (1992)	
	EL	Kirchhofer et al., "The Tissue Factor Region That Interacts with Factor Xa in the Activation of Factor VII," Biochemistry, 40:675-682 (2001)	
	EM	Kumar et al., "Identification of Molecular Sites on Factor VII Which Mediate Its Assembly and Function in the Extrinsic Pathway Activation Complex," The Journal of Biological Chemistry, 266(2):915-921 (1991)	
	EN	Kumar et al., "Specific molecular interaction sites on factor VII involved in factor X activation," Eur. J. Biochem. 217:509-518 (1993)	
	EO	Levi et al., "Inhibition of Endotoxin-induced Activation of Coagulation and Fibrinolysis by Pentoxifylline or by a Monoclonal Anti-tissue factor Antibody in Chimpanzees," The Journal of Clinical Investigation, Inc., 93:114-120 (1994)	
	EP	Maekawa et al., "Complement-Dependent Immunosuppressive Anti-Tissue Factor Monoclonal Antibody: The Establishment of Monoclonal Antibodies and Their Effect on Mixed Lymphocyte Reaction," Transplantation Proceedings, 25(4):2713-2715 (1993)	
	EQ	Martin et al., Activation of Factor X by Factor VIIa on Monocyte Cell Surfaces, pp. 3828 - 3829 Blood. 1994 Jun 15;83(12):3828-9.	
	ER	Martin et al., "Tissue Factor: molecular recognition and cofactor function," The FASEB Journal, 9:852-859 (1995)	
	ES	Masuda et al., "Association of tissue factor with a γ chain homodimer of the IgE receptor type I in cultured human monocytes," Eur. J. Immunol., 26:2529-2532 (1996)	
	ET	McGee et al., "Functional Difference between Intrinsic and Extrinsic Coagulation Pathways," The Journal of Biological Chemistry, 266(13):8079-8085 (1991)	

Examiner Signature		Date Considered	

PTO/SB/08a/b (07-06)
Approved for use through 09/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 6 of 9

Complete if Known	
Application Number	10/764,140-Conf. #6085
Filing Date	January 22, 2004
First Named Inventor	Jin-An Jiao
Art Unit	1647
Examiner Name	C. M. Borgeest
Attorney Docket Number	TNA-00505

	EU	Merriam-Webster Online dictionary, downloaded October 11, 2005, world wide web at m-w.com, definition of thrombosis, 2 pages	
	EV	Morrissey et al., "Monoclonal Antibody Analysis of Purified and Cell-Associated Tissue Factor," Thrombosis Research, 52:247-261 (1988)	
	EW	Morrissey et al., "Resolution of Monomeric and Heterodimeric Forms of Tissue Factor, the High-Affinity Cellular Receptor for Factor VII," Thrombosis Research, 50:481-493 (1988)	
	EX	Mueller, Barbara M., Expression of Tissue Factor by Melanoma Cells Promotes Efficient Hematogenous Metastasis, Proc. Natl. Acad. Sci. USA, December 1992, Vol. 89, pp. 11832-11836	
	EY	Muller et al., "Structure of the Extracellular Domain of Human Tissue Factor: Location of the Factor VIIa Binding Site," American Chemical Society, (1994)	
	EZ	Nemerson et al., "An Ordered Addition, Essential Activation Model of the Tissue Factor Pathway of Coagulation: Evidence for a Conformational Cage," Biochemistry, 25:4020-4033 (1986)	
	FA	Noguchi et al., "Correlation Between Antigenic and Functional Expression of Tissue Factor on the Surface of Cultured Human Endothelial Cells Following Stimulation by Lipopolysaccharide Endotoxin," Thrombosis Research, 55:87-97 (1989)	
	FB	Østerud et al., "The Interaction of Human Blood Coagulation Factor VII and Tissue Factor: The Effect of Anti Factor VII, Anti Tissue Factor and Diisopropylfluorophosphate," Biochemical and Biophysical Research Communications, 88(1):59-67 (1979)	
	FC	Pawashe et al., A Monoclonal Antibody Against Rabbit Tissue Factor Inhibits Thrombus Formation in Stenotic Injured Rabbit Carotid Arteries, Tissue Factor and Intravascular Thrombosis, January 1994, Vol. 74, No. 1, pp. 56-63	
	FD	Ploplis et al., Initiation of the Extrinsic Pathway of Coagulation - Association of Factor VIIa with a Cell Line Expressing Tissue Factor, The Journal of Biological Chemistry, July 15, 1987, Vol. 262, pp. 9503-9508	
	FE	Price et al., "Tissue factor and tissue factor pathway inhibitor," Anaesthesia, 59:483-492 (2004)	
	EF	Rehemtulla et al., The Integrity of the Cysteine 186-Cysteine 209 Bond of the Second Disulfide Loop of Tissue Factor Is Required for Binding of Factor VII, The Journal of Biological Chemistry, June 5, 1991, Vol. 266, No. 16, pp. 10294-10299	
	EG	Ruf et al., "An Anti-Tissue Factor Monoclonal Antibody Which Inhibits TF-VIIa Complex Is a Potent Anticoagulant in Plasma, Thrombosis and Haemostasis," F.K. Schattauer Verlagsgesellschaft mbH (Stuttgart) 66 (5) 529-533 (1991)	
	EH	Ruf et al., "Antibody Mapping of Tissue Factor Implicates Two Different Exon-Encoded Regions in Function," Biochem J. (1991) 278, pp. 729-733	
	EI	Ruf et al., "Characterization of Factor VII Association with Tissue Factor in Solution - High and Low Affinity Calcium Binding Sites in Factor VII Contribute to Functionally Distinct Interactions," The Journal of Biological Chemistry, Vol. 266, August 25, 1991, pp. 15719-15725	
	EJ	Ruf et al., "Phospholipid-independent and -dependent Interactions Required for Tissue Factor Receptor and Cofactor Function," The Journal of Biological Chemistry, February 5, 1991, Vol. 266, pp. 2158-2166	
	EK	Ruf et al., "Structural Biology of Tissue Factor, the Initiator of Thrombogenesis in Vivo," The FASEB Journal, April 1994, Vol. 8, pp. 385-390	
	EL	Ruf et al., "Tissue Factor Residues 157-167 Are Required for Efficient Proteolytic Activation of Factor X and Factor VII," The Journal of Biological Chemistry, November 5, 1992, Vol. 267, No. 31, pp. 22206-22210	
	EM	Ruf et al., "Two Sites in the Tissue Factor Extracellular Domain Mediate the Recognition of the Ligand Factor VIIa," Proc. Natl. Acad. Sci. USA, October 1991, Vol. 88, pp. 8430-8434	

Examiner Signature		Date Considered	

PTO/SB/08a/b (07-06)
Approved for use through 09/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/764,140-Conf. #6085
				Filing Date	January 22, 2004
				First Named Inventor	Jin-An Jiao
				Art Unit	1647
(Use as many sheets as necessary)				Examiner Name	C. M. Borgeest
Sheet	7	of	9	Attorney Docket Number	TNA-00505

	EN	Ryan et al., "Tumor Necrosis Factor-Induced Endothelial Tissue Factor Is Associated With Subendothelial Matrix Vesicles But Is Not Expressed on the Apical Surface," Blood, August 15, 1992, Vol. 80, No. 4, pp. 966-974	
	EO	Sakai et al., "Binding of Human Factors VII and VIIa to a Human Bladder Carcinoma Cell Line (J82) - Implications For The Initiation of the Extrinsic Pathway of Blooad Coagulation," The Journal of Biological Chemistry, Vol. 264, No. 17, June 15, 1989, pp. 9980-9988	
	EP	Salatti et al., "Modulation of Procoagulant Activity of Extracellular Endothelial Matrix by Anti-Tissue Factor Antibody and the Synthetic Peptide Arg-Gly-Asp-Val. Experiments with Flowing Non-Anticoagulated Human Blood," Blood Coagulation and Fibrinolysis, 1993, Vol. 4, pp. 881-890	
	EQ	Sandset et al., "Immunodepletion of Extrinsic Pathway Inhibitor Sensitizes Rabbits to Endotoxin-Induced Intravascular Coagulation and the Generalized Shwartzman Reaction," Blood, September 15, 1991, Vol. 78, No. 6, pp. 1496-1502	
	ER	Speidel et al., "Procoagulant Activity on Injured Arteries and Associated Thrombi Is Mediated Primarily by the Complex of Tissue Factor and Factor VIIa," Pathophysiology and Natural History, Coronary Artery Disease, January 1996, Vol. 7, No. 1, pp. 58-62	
	ES	Stephens et al., "Production of Tissue Factor By Monocyte Porgenitor Cells," Thrombosis Research, 1994, Vol. 76, No. 1, pp. 33-45	
	ET	Sturm et al., "Immunohistological Detection of Tissue Factor in Normal and Abnormal Human Mammary Glands Using Monoclonal Antibodies," Virchows Archiv A Pathological Anatomy and Histopathology, 1992, 421:79-86	
	EU	Toomey et al., "Localization of the Human Tissue Factor Recognition Determinant of Human Factor VIIa," The Journal of Biological Chemistry, October 15, 1991, Vol. 266, No. 29, pp. 19198-19202	
	EV	Tsao et al., "Monocytes Can Be Induced by Lipopolysaccharide-Triggered T Lymphocytes To Express Functional Factor VII/VIIa Protease Activity," J. Exp. Med., April 1984, Vol. 159, pp. 1042-1057	
	EW	Tsuda et al., "Development of Antitissue Factor Antibodies in Patients After Liver Surgery," Blood, Vol. 82, No. 1 July 1, 1993, pp. 96-102	
	EX	Walsh et al., "Discordant Expression of Tissue Factor Antigen and Procoagulant Activity on Human Monocytes Activated with LPS and Low Dose Cycloheximide," Thrombosis and Haemostasis, F.K. Achattauer Verlagsgesellschaft mbH (Stuttgart), 1991, 66 (5), pp. 552-558	
	EY	Warr et al., "Disseminated Intravascular Coagulation in Rabbits Induced by Administration of Endotoxin or Tissue Factor: Effect of Anti-Tissue Factor Antibodies and Measurement of Plasma Extrinsic Pathway Inhibitor Activity," Blood, Vol. 75, No. 7, April 1, 1990, pp. 1481-1489	
	EZ	Camerer et al., "Tissue Factor - And Factor X-Dependent Activation of Protease-Activated Receptor 2 by Factor VIIa," PNAS, 97(10):5255-5260 (2000)	
	FA	Ruf et al., "Tissue Factor Signaling," Thrombosis and Haemostasis, 82(2):175-182 (1999)	
	FB	Ollivier et al., "Tissue Factor-Dependent Vascular Endothelial Growth Factor Production by Human Fibroblasts in Response to Activated Factor VII," Blood, 91(8):2698-2703 (1998)	
	FC	Wiiger et al., "Effects of Binding of Ligand (FVIIa) to Induced Tissue Factor in Human Endothelial Cells," Thrombosis Research, 98:311-321 (2000)	
	FD	Konigsberg et al., "The TF:VIIa Complex: Clinical Significance, Structure-Function Relationships and Its Role in Signaling and Metastasis," Thrombosis Haemostasis, 86:757-771 (2001)	
	FE	Riewald et al., "Mechanistic Coupling of Protease Signaling and Initiation of Coagulation by Tissue Factor," PNAS, 98(14):7742-7747 (2001)	
	FF	Mueller et al, "Expression of Tissue Factor by Melanoma Cells Promote Efficient Hematogenous Metastasis," Proc. Natl. Acad. Sci. USA, 89:11832-11836 (1992)	

Examiner Signature		Date Considered	

PTO/SB/08a/b (07-06)
Approved for use through 09/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 8 of 9

Complete if Known	
Application Number	10/764,140-Conf. #6085
Filing Date	January 22, 2004
First Named Inventor	Jin-An Jiao
Art Unit	1647
Examiner Name	C. M. Borgeest
Attorney Docket Number	TNA-00505

	FG	Poster Presentation Experimental Biology 2001, March 31-April 4, 2001, Orlando, Florida, Anti-Tissue Factor Antibodies	
	FH	Francis et al., "Effect of Antihemostatis Agents on Experimental Tumor Dissemination," Sem. in Thrombosis and Haemostasis, 28(1):29-38 (2002)	
	FI	Amirkhosravi et al., "The Suppression of Tumor Cell Procoagulant Activity, Experimental Metastasis and Primary Tumor Growth by Monoclonal Antibodies Against Tissue Factor," Suppl. to J. of Thrombosis and Haemostasis Abstract:OC1021 (2001)	
	CF	Wen, Jinghai et al. "Antibody-dependent cellular cytotoxicity and antibody dependent cellular phgocytosis of breast cancer cells mediated by anti-tissue factor monoclonal antibodies," FASEB Journal, 15(5):A1198 (2001) Annual Meeting of the Federation of American Societies for Experimental Biology on Experimental Biol; Orlando, Florida, March 31-April 4, 2001 Abstract	
	CG	Chothia et al., "The outline structure of the T-Cell αβ receptor," The EMBO Journal, 7(12):3745-3755 (1988)	
	CJ	Gascoigne et al., "Secretion of a chimeric T-cell receptor-immunoglobulin protein," Proc. Natl. Acad. Sci. USA, 84:2936-2940 (1987)	
	CK	George et al., "Current Methods in Sequence Comparison and Analysis," Marcomolecular Sequencing and Synthesis, Alan Riss, 127-149 (1988)	
	CL	Gregoire et al., "Engineered secreted T-cell receptor αβ heterodimers," Proc. Natl. Acad. Sci. USA, 88:8077-8081 (1991)	
	CM	Groves et al., "Production of an ovine monoclonal antibody to testosterone by an interspecies fusion," Hybriodoma, 6(1):71-76 (1987)	
	CO	Kappler et al., "Binding of a soluble αβ T-cell receptor to superantigen/major histocompatibility complex ligands," Proc. Natl. Acad. Sci. USA, 91:8462-8466 (1994)	
	CP	Kurucz et al., "A bacterially expressed single-chain Fv construct from the 2B4 T-cell receptor," Proc. Natl. Acad. Sci. USA, 90:3830-3834 (1993)	
	CQ	Lin et al., "Expression of T cell antigen receptor herodimers in a lipid-linked form," Science, 249:677-679 (1990)	
	CR	Mariuzza et al., "Secretion of a Homodimeric $V_\alpha C_\kappa$ T-cell Receptor-Immunoglobulin Chimeric Protein," The Journal of Biological, 264(13):7310-7316 (1989)	
	CS	Morrison, SL, "In vitro antibodies: strategies for production and application," Ann. Rev. Immunol., 10:239-265 (1992)	
	CT	Novotny et al., "A soluble, single-chain T-cell receptor fragment endowed with antigen-combining properties," Proc. Natl. Acad. Sci. USA, 88:8646-8650 (1991)	
	CU	Onda et al., "A phage display system for detection of T cell receptor-antigen interactions," Molecular Immunology, 32(17-18):1387-1397 (1995)	
	CV	Parmley et al., "Antibody-selectable filamentous fd phage vectors: affinity purification of target genes," Gene, 73:305-318 (1988)	
	CW	Presta et al., "Generation of a Humanized High Affinity Anti-Tissue Factor Antibody for Use as a Novel Antithrombotic Therapeutic," Thromb Haemost 85:379-89 (2001)	
	CX	Ragni et al., "Monoclonal Antibody Against Tissue Factor Shortens Tissue Plasminogen Activator Lysis Time and Prevents Reocclusion in a Rabbit Model of Carotid Artery Thrombosis," Circulation, 93:1913-1918 (1996)	
	CY	Rao et al., "Purification and characterization of rabbit tissue factor," Thrombosis Research, 56:109-118 (1989)	
	CZ	Schlueter et al., "Specificity and binding properties of a single-chain T cell receptor," J. Mol. Biol., 256:859-869 (1996)	
	DA	Smith et al., "Libraries of Peptides and Proteins Displayed on Filamentous Phage," Methods in Enzymology, 217:228-257 (1993)	
	DB	Soo Hoo et al., "Characterization of a single-chain T-cell receptor expressed in Escherichia coli," Proc. Natl. Acad. Sci. USA, 89:4759-4763 (1992)	

Examiner Signature		Date Considered	

PTO/SB/08a/b (07-06)
Approved for use through 09/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	9	of	9

Complete if Known	
Application Number	10/764,140-Conf. #6085
Filing Date	January 22, 2004
First Named Inventor	Jin-An Jiao
Art Unit	1647
Examiner Name	C. M. Borgeest
Attorney Docket Number	TNA-00505

	DC	Ward, E. S., "Expression and Secretion of T-Cell Receptor Vα and Vβ Domains using Escherichia coli as a Host," Scand. J. Immunol., 34:215-220 (1991)	
	DE	Wulfing et al., "Correctly folded T-cell receptor fragments in the periplasm of Escherichia coli. Influence of folding catalysts," J. Mol. Biol., 242:655-669 (1994)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	